BALTIMORE, Nov. 18, 2016 /PRNewswire/ -- Paragon Bioservices, Inc., a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today the appointment of Ruby Hofmann to the position of Vice President, Human Resources and Organizational Development, where she will focus on accelerating our talent acquisition/recruiting efforts and helping the company continue to build something special by developing and implementing best-in-class employee programs.
"Our employees are the backbone of Paragon Bioservices and our ability to attract, retain and develop talent are paramount to our success. We now have near 165 employees with many new openings as we expand our GMP capabilities. Ruby's leadership skills and strong track record of recruiting and growing companies will help us accomplish our strategy of becoming the preferred CDMO for Vaccine and Viral Vector Gene Therapy technologies. We welcome Ruby to the leadership team and look forward to her contributions in playing a key role in the Company's growth agenda," stated Peter Buzy, President and CEO of Paragon.
Ms. Hofmann brings over 20 years of experience in progressively responsible positions in the Human Resource field. Her early career was spent in the Financial Services industry and through her consulting engagements she successfully managed strategic projects with multi-million-dollar, international companies such as Brother International, Bristol-Myers Squibb, DSM, Catalent and PharmaNet/i3. Ms. Hofmann has significant experience in change management and HR/business model transformation, and much of her work has involved establishing global talent acquisition strategies, developing talent management programs and coaching executive leadership teams.
Ms. Hofmann earned her BA in Psychology from Hofstra University and her MS in Social Work from Columbia University.
About Paragon Bioservices, Inc. Paragon Bioservices is a private‐equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticals—including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon's cGMP facilities include microbial and mammalian suites, fill‐finish and fully‐segregated virus facilities.
Media Contact Philip W Wills, PhD, VP Business Development & Principal Scientist PH (410) 975-4050